Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Cambridge, MA, March 17, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the fourth quarter and full-year ended December 31, 2020. Note: A glossary of terms has been added to the end of this document in...
Category: News
Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral XENLETA DUBLIN, Ireland, March 16, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative...
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and...
Melinta Therapeutics Announces Appointment of Kristen Allgor as Chief Human Resources Officer
MORRISTOWN, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) — Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced the appointment of Kristen Allgor as Chief Human Resources Officer, effective today. In August of this year, Christine Ann Miller, a global pharmaceutical veteran, joined Melinta as President and...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
–-NDA for Oral Sulopenem has PDUFA date of July 25, 2021— –-Cash Runway into First Half of 2023— –Company to host conference call today at 8:30amET– DUBLIN, Ireland and CHICAGO, March 12, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing...
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
-Relaunched XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community with 60 sales representatives- -Nabriva plans to initiate a Phase 1 clinical trial of XENLETA in patients with cystic fibrosis- -Conference call today at 4:30 p.m. Eastern Time– DUBLIN, Ireland, March 11, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged...
Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate
VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021
Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer
MORRISTOWN, NEW JERSEY, August 3, 2020— Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020. In April of this year, Melinta...
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release...
Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021
DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2020 financial results along with recent company highlights after the close of the...